Tourmaline Bio Inc. Cash Flow Conversion Efficiency
Tourmaline Bio Inc. cash flow conversion efficiency. Based on the latest financial reports, Tourmaline Bio Inc. (TRML) has a cash flow conversion efficiency ratio of -0.078x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.26 Million) by net assets ($259.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tourmaline Bio Inc. (2019–2024)
Cash flow conversion efficiency of Tourmaline Bio Inc. from 2019 to 2024. This chart illustrates how Tourmaline Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Tourmaline Bio Inc. stock price today for real-time trading data and today's change.
Tourmaline Bio Inc. Cash Flow Conversion Ratio Explained
Tourmaline Bio Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tourmaline Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tourmaline Bio Inc. ranked by their cash flow conversion efficiency. Also see TRML market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rizhao Port Co Ltd
SHG:600017
|
0.017x |
|
Vitec Software Group AB (publ)
ST:VIT-B
|
0.018x |
|
Asuransi Jiwa Sinarmas Msig PT
JK:LIFE
|
0.023x |
|
Biotage AB
ST:BIOT
|
0.011x |
|
Valeura Energy Inc
TO:VLE
|
0.212x |
|
Gemadept Corp
VN:GMD
|
0.103x |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
0.022x |
|
VA Tech Wabag Limited
NSE:WABAG
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Tourmaline Bio Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tourmaline Bio Inc. from 2019 to 2024. Review TRML cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $300.05 Million | $-77.26 Million | -0.257x | -88.02% |
| 2023-12-31 | $205.04 Million | $-28.08 Million | -0.137x | -141.84% |
| 2022-12-31 | $-19.73 Million | $-6.46 Million | 0.327x | +298.73% |
| 2021-12-31 | $242.81 Million | $-39.99 Million | -0.165x | -26.87% |
| 2020-12-31 | $148.00 Million | $-19.21 Million | -0.130x | +70.90% |
| 2019-12-31 | $39.59 Million | $-17.66 Million | -0.446x | -- |
About Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline c… Read more